BR0111596A - Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças - Google Patents
Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doençasInfo
- Publication number
- BR0111596A BR0111596A BR0111596-0A BR0111596A BR0111596A BR 0111596 A BR0111596 A BR 0111596A BR 0111596 A BR0111596 A BR 0111596A BR 0111596 A BR0111596 A BR 0111596A
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- group
- denotes
- preventing
- pharmaceutical composition
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 6
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 abstract 1
- 102000003678 AMPA Receptors Human genes 0.000 abstract 1
- 108090000078 AMPA Receptors Proteins 0.000 abstract 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000004677 hydrates Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/69—Two or more oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/84—Nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-175.966 | 2000-06-12 | ||
JP2000175966 | 2000-06-12 | ||
GB0022483A GB0022483D0 (en) | 2000-09-13 | 2000-09-13 | 1 2 Dihydropyridine compounds manufacturing method thereof and use thereof |
GB0022483.2 | 2000-09-13 | ||
PCT/JP2001/004857 WO2001096308A1 (fr) | 2000-06-12 | 2001-06-08 | Composes 1,2-dihydropyridine, leur procede de preparation et leur utilisation |
Publications (4)
Publication Number | Publication Date |
---|---|
BR0111596A true BR0111596A (pt) | 2004-03-02 |
BRPI0111596B1 BRPI0111596B1 (pt) | 2018-10-02 |
BRPI0000596B8 BRPI0000596B8 (pt) | 2021-05-25 |
BRPI0111596B8 BRPI0111596B8 (pt) | 2022-07-26 |
Family
ID=26244997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0111596A BRPI0111596B8 (pt) | 2000-06-12 | 2001-06-08 | Composto piridona, processo de produção do composto, composição farmacêutica, e uso do dito composto |
Country Status (27)
Country | Link |
---|---|
US (3) | US6949571B2 (pt) |
EP (3) | EP1300396B1 (pt) |
JP (3) | JP3922368B2 (pt) |
KR (3) | KR100904011B1 (pt) |
CN (1) | CN1245386C (pt) |
AT (1) | ATE420862T1 (pt) |
AU (2) | AU2001262723C1 (pt) |
BE (1) | BE2013C003I2 (pt) |
BR (1) | BRPI0111596B8 (pt) |
CA (1) | CA2412172C (pt) |
CY (2) | CY1108969T1 (pt) |
DE (1) | DE60137426D1 (pt) |
DK (1) | DK1300396T3 (pt) |
ES (1) | ES2320973T3 (pt) |
FR (1) | FR12C0074I2 (pt) |
HK (1) | HK1056871A1 (pt) |
HU (2) | HU229553B1 (pt) |
IL (5) | IL152848A0 (pt) |
LU (1) | LU92113I2 (pt) |
MX (1) | MXPA02012314A (pt) |
NL (1) | NL300565I1 (pt) |
NO (2) | NO325160B1 (pt) |
NZ (1) | NZ522773A (pt) |
PT (1) | PT1300396E (pt) |
TW (2) | TW200815402A (pt) |
WO (1) | WO2001096308A1 (pt) |
ZA (1) | ZA200209270B (pt) |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL152848A0 (en) * | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
AU2002237664A1 (en) * | 2000-11-20 | 2002-05-27 | Bristol-Myers Squibb Company | Pyridone derivatives as AP2 inhibitors |
US20030105144A1 (en) | 2001-04-17 | 2003-06-05 | Ping Gao | Stabilized oral pharmaceutical composition |
JP4119114B2 (ja) * | 2001-11-28 | 2008-07-16 | 広栄化学工業株式会社 | 新規なジヒドロキシ(3−ピリジル)ボラン類 |
GB0129260D0 (en) * | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
WO2003059884A1 (en) | 2001-12-21 | 2003-07-24 | X-Ceptor Therapeutics, Inc. | Modulators of lxr |
US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
WO2003079986A2 (en) | 2002-03-18 | 2003-10-02 | Bristol-Myers Squibb Company | Uracil derivatives as inhibitors of tnf-alpha converting enzyme (tace) and matrix metalloproteinases |
AU2003222832A1 (en) * | 2002-04-19 | 2003-11-03 | Glaxo Group Limited | Compounds having affinity at 5ht2c receptor and use thereof in therapy |
JP4208512B2 (ja) * | 2002-07-23 | 2009-01-14 | 株式会社クラレ | 5−(2’−ピリジル)−2−ピリドン誘導体の製造方法 |
WO2004035563A1 (en) * | 2002-10-17 | 2004-04-29 | Syngenta Participations Ag | 3-heterocyclylpyridine derivatives useful as herbicides |
WO2004055007A1 (en) * | 2002-12-16 | 2004-07-01 | Mitsubishi Pharma Corporation | 3-substituted-4-pyrimidone derivatives |
US7189716B2 (en) * | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
GB0305024D0 (en) * | 2003-03-05 | 2003-04-09 | Glaxo Group Ltd | Compounds |
SE0302324D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
SE0302323D0 (sv) * | 2003-08-28 | 2003-08-28 | Astrazeneca Ab | Novel compounds |
SE0302486D0 (sv) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
MY148809A (en) * | 2004-07-06 | 2013-05-31 | Eisai R&D Man Co Ltd | Crystals of 1,2-dihydropyridine compound and their production process |
JP2007099781A (ja) * | 2004-07-06 | 2007-04-19 | Eisai R & D Management Co Ltd | 1,2−ジヒドロピリジン化合物の結晶の製造方法 |
GB0420722D0 (en) * | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
US20060069260A1 (en) * | 2004-09-28 | 2006-03-30 | Huiping Zhang | Preparation of N-aryl pyridones |
EP1831168B1 (en) | 2004-12-16 | 2014-07-02 | Vertex Pharmaceuticals Inc. | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases. |
EP1858325A4 (en) * | 2005-01-07 | 2010-06-30 | Roskamp Res Llc | COMPOUNDS FOR INHIBITING BETA-AMYLOID PRODUCTION AND METHODS FOR IDENTIFYING THESE COMPOUNDS |
TW200700392A (en) * | 2005-03-16 | 2007-01-01 | Astrazeneca Ab | Novel compounds |
AU2006232517A1 (en) * | 2005-04-04 | 2006-10-12 | Eisai R&D Management Co., Ltd. | Dihydropyridine compounds and compositions for headaches |
WO2006109876A1 (ja) * | 2005-04-08 | 2006-10-19 | Eisai R & D Management Co., Ltd. | 不随意運動治療剤 |
ES2600460T3 (es) | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
GB0510141D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B3 |
JP2009503103A (ja) * | 2005-08-02 | 2009-01-29 | レキシコン・ファーマシューティカルズ・インコーポレーテッド | アリールピリジン及びその使用方法 |
US7786130B2 (en) | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
US7786120B2 (en) | 2005-08-29 | 2010-08-31 | Vertex Pharmaceuticals Incorporated | Pyridones useful as inhibitors of kinases |
ATE548363T1 (de) | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
EP1932840B1 (en) | 2005-10-03 | 2014-04-09 | Ono Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic compound and pharmaceutical application thereof |
JPWO2007072868A1 (ja) * | 2005-12-21 | 2009-06-04 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 1,2−ジヒドロピリジン化合物の結晶(iv型) |
WO2007072869A1 (ja) * | 2005-12-21 | 2007-06-28 | Eisai R & D Management Co., Ltd. | 1,2-ジヒドロピリジン化合物の非晶質体 |
JP4865337B2 (ja) * | 2006-01-24 | 2012-02-01 | 富士フイルムファインケミカルズ株式会社 | 2,3’−ビピリジル−6’−オンの製造方法 |
TWI417095B (zh) | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
WO2007126060A1 (ja) * | 2006-04-28 | 2007-11-08 | Eisai R & D Management Co., Ltd | 1,2-ジヒドロピリジン化合物の塩 |
TW200808763A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds I |
TW200808771A (en) | 2006-05-08 | 2008-02-16 | Astrazeneca Ab | Novel compounds II |
US20080108622A1 (en) * | 2006-10-19 | 2008-05-08 | Eisenach James C | Combination therapy for the treatment of pain |
US20080108603A1 (en) * | 2006-10-19 | 2008-05-08 | Eisenach James C | Combination therapy for the treatment of pain |
EP2131828A2 (en) * | 2007-03-05 | 2009-12-16 | Eisai R&D Management Co., Ltd. | Ampa and nmda receptor antagonists for neurodegenerative diseases |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
JP2010524844A (ja) * | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 認知症のためのシンナミド化合物 |
CA2690086A1 (en) * | 2007-07-13 | 2009-01-22 | Masanori Tsuno | Ampa receptor antagonists and aldose reductase inhibitors for neuropathic pain |
EP2164489A2 (en) * | 2007-07-13 | 2010-03-24 | Eisai R&D Management Co., Ltd. | Combination of ampa receptor antagonists and acetylcholinesterase inhibitors for the treatment of neuropathic pain |
MX2010002537A (es) | 2007-09-14 | 2010-08-10 | Ortho Mcneil Janssen Pharm | 4-fenil-1h-piridin-2-onas 1,3-disubstituidas. |
ES2365966T3 (es) | 2007-09-14 | 2011-10-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 4-(aril-x-fenil)-1h-piridin-2-onas 1,3-disustituidas. |
PT2203439E (pt) | 2007-09-14 | 2011-02-11 | Ortho Mcneil Janssen Pharm | 4-fenil-3,4,5,6-tetra-hidro-2h,1'h-[1,4']bipiridinil-2'- onas 1',3'-dissubstituídas |
WO2009054544A1 (en) * | 2007-10-26 | 2009-04-30 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for parkinson's disease and movement disorders |
AU2008325288B2 (en) * | 2007-11-06 | 2011-12-22 | Astrazeneca Ab | Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastase |
CN101861316B (zh) | 2007-11-14 | 2013-08-21 | 奥梅-杨森制药有限公司 | 咪唑并[1,2-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
EP2223912A4 (en) | 2007-12-21 | 2012-04-25 | Kuraray Co | PROCESS FOR THE PREPARATION OF A 6-HALOGENO-3-ARYLPYRIDINE DERIVATIVE |
US20100256191A1 (en) * | 2007-12-26 | 2010-10-07 | Eisai R&D Management Co., Ltd. | Ampa receptor antagonists and zonisamide for epilepsy |
JP2011507800A (ja) * | 2007-12-26 | 2011-03-10 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 癲癇、精神障害、または感覚器官の障害のためのampa受容体アンタゴニスト |
AU2009244504A1 (en) * | 2008-05-05 | 2009-11-12 | Amgen Inc. | Urea compounds as gamma secretase modulators |
CA3034994A1 (en) | 2008-06-03 | 2009-12-10 | Intermune, Inc. | Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders |
US8859760B2 (en) | 2008-07-29 | 2014-10-14 | Frontier Scientific, Inc. | Compositions for killing or preventing the growth of microbes |
CA2735764C (en) | 2008-09-02 | 2016-06-14 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors |
CA2738849C (en) | 2008-10-16 | 2016-06-28 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
ES2534199T3 (es) * | 2008-10-31 | 2015-04-20 | Merck Sharp & Dohme Corp. | Antagonistas del receptor P2X3 para el tratamiento del dolor |
MX2011005242A (es) | 2008-11-28 | 2011-09-06 | Ortho Mcneil Janssen Pharm | Derivados de indol y benzoxazina como moduladores de los receptores de glutamato metabotropicos. |
CN102264701A (zh) | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 作为p2x7调节剂的二氢吡啶酮脲 |
US8153808B2 (en) | 2008-12-23 | 2012-04-10 | Roche Palo Alto Llc | Dihydropyridone amides as P2X7 modulators |
CA2747925A1 (en) | 2008-12-23 | 2010-07-01 | F. Hoffmann-La Roche Ag | Dihydropyridone amides as p2x7 modulators |
SG172336A1 (en) | 2008-12-23 | 2011-07-28 | Hoffmann La Roche | Dihydropyridone amides as p2x7 modulators |
EP2382202A1 (en) | 2008-12-23 | 2011-11-02 | F. Hoffmann-La Roche AG | Dihydropyridone amides as p2x7 modulators |
TW201036957A (en) | 2009-02-20 | 2010-10-16 | Astrazeneca Ab | Novel salt 628 |
CA2756870A1 (en) | 2009-03-31 | 2010-10-07 | Arqule, Inc. | Substituted indolo-pyridinone compounds |
AR076859A1 (es) | 2009-05-12 | 2011-07-13 | Ortho Mcneil Janssen Pharm | Derivados de 1,2,4-triazolo[4,3-a]piridina moduladores alostericos positivos de receptores mglur2 , composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos neurologicos y siquiatricos. |
MX2011011964A (es) | 2009-05-12 | 2012-02-23 | Janssen Pharmaceuticals Inc | Derivados de 1,2,3-triazolo[4,3-a]piridina y su uso para el tratamiento o prevencion de trastornos neurologicos y psiquiatricos. |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP2013506649A (ja) | 2009-10-02 | 2013-02-28 | アストラゼネカ・アクチエボラーグ | 好中球エラスターゼの阻害剤として使用する2−ピリドン化合物 |
JP2013234123A (ja) * | 2010-09-03 | 2013-11-21 | Taisho Pharmaceutical Co Ltd | 3−ピラゾリル−2−ピリドン誘導体 |
PL2649069T3 (pl) | 2010-11-08 | 2016-01-29 | Janssen Pharmaceuticals Inc | Pochodne 1,2,4-triazolo[4,3-a]pirydyny i ich zastosowanie jako dodatnich allosterycznych modulatorów receptorów mGluR2 |
CN103298809B (zh) | 2010-11-08 | 2016-08-31 | 杨森制药公司 | 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途 |
CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EP2648516B1 (en) * | 2010-12-06 | 2018-09-05 | Aclaris Therapeutics, Inc. | Substituted pyridinone-pyridinyl compounds |
WO2012121863A1 (en) | 2011-03-04 | 2012-09-13 | Yale University | (--)- huperzine a processes and related compositions and methods of treatment |
ITMI20111952A1 (it) | 2011-10-27 | 2013-04-28 | Italiana Sint Spa | Procedimento per la prepazione di 2-metossi-5-(piridin-2-il)piridina, un intermedio del perampanel |
US9096574B2 (en) | 2012-01-03 | 2015-08-04 | Mapi Pharma Ltd. | Polymorphs of perampanel |
CN104254526B (zh) * | 2012-03-31 | 2017-06-20 | 乔治亚大学研究基金公司 | 针对结核病的新的抗分枝杆菌药物 |
BR112014030284B1 (pt) * | 2012-07-18 | 2021-11-30 | Sunshine Lake Pharma Co., Ltd | Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica |
ITMI20121390A1 (it) | 2012-08-06 | 2014-02-07 | F I S Fabbrica Italiana Sint P A | Procedimento per la preparazione di acido 2-cianofenilboronico e suoi esteri, intermedi del perampanel o di e2040 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
JO3225B1 (ar) * | 2012-11-27 | 2018-03-08 | Lilly Co Eli | 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8 |
TW201441193A (zh) | 2012-12-06 | 2014-11-01 | Kyowa Hakko Kirin Co Ltd | 吡啶酮化合物 |
US9242969B2 (en) | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
US20160045625A1 (en) * | 2013-04-04 | 2016-02-18 | Eisai R&D Management Co., Ltd. | [11c] and [18f] labeled 1,3-diphenyl-5-(pyrimidin-2-yl)-pyridin-2(1h)-one derivatives and their use for pet imaging of the ampa receptor |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
CN103274993A (zh) * | 2013-06-13 | 2013-09-04 | 南京工业大学 | 二氢吡啶和吡咯类杂环的新合成方法 |
EP3024821B1 (en) * | 2013-07-25 | 2017-09-27 | Teva Pharmaceuticals International GmbH | Process for the preparation of perampanel |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
EP3063139B1 (en) | 2013-10-29 | 2018-11-21 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
CN103664756A (zh) * | 2013-11-26 | 2014-03-26 | 苏州晶云药物科技有限公司 | 吡仑帕奈新晶型a及其制备方法 |
CN104706604A (zh) * | 2013-12-12 | 2015-06-17 | 北京星昊医药股份有限公司 | 一种吡仑帕奈冻干口崩片及其制备方法 |
CN104725301A (zh) * | 2013-12-20 | 2015-06-24 | 北京蓝贝望生物医药科技股份有限公司 | 一种1,2-二氢吡啶-2-酮衍生物的制备方法 |
AU2015208233B2 (en) | 2014-01-21 | 2019-08-29 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
PT3096790T (pt) | 2014-01-21 | 2019-10-15 | Janssen Pharmaceutica Nv | Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso |
KR102373700B1 (ko) | 2014-04-02 | 2022-03-11 | 인터뮨, 인크. | 항섬유성 피리디논 |
CN105085382B (zh) * | 2014-05-14 | 2019-10-18 | 江苏豪森药业集团有限公司 | 吡仑帕奈异构体晶型及其制备方法和用途 |
TW201609719A (zh) | 2014-05-28 | 2016-03-16 | 美國禮來大藥廠 | 作為TARP-γ8依賴性AMPA受體拮抗劑之6-經取代-3H-1,3-苯并噻唑-2-酮化合物 |
CN103980188B (zh) * | 2014-05-30 | 2016-01-27 | 浙江永宁药业股份有限公司 | 一种吡仑帕奈的合成方法及其中间体和中间体的合成方法 |
UY36294A (es) | 2014-09-12 | 2016-04-29 | Novartis Ag | Compuestos y composiciones como inhibidores de quinasa |
US10227328B2 (en) | 2015-02-04 | 2019-03-12 | Beyondbio Inc. | Heterocyclic compound and pharmaceutical composition comprising same |
WO2016132343A1 (en) * | 2015-02-17 | 2016-08-25 | Mapi Pharma Ltd. | Process and intermediates for the preparation of perampanel |
AR104259A1 (es) * | 2015-04-15 | 2017-07-05 | Celgene Quanticel Res Inc | Inhibidores de bromodominio |
WO2016172333A1 (en) | 2015-04-21 | 2016-10-27 | Teva Pharmaceuticals International Gmbh | A solid state form of perampanel |
RU2705595C2 (ru) | 2015-07-06 | 2019-11-11 | Паблик Юниверсити Корпорейшн Йокогама Сити Юниверсити | Новое соединение, специфически связывающееся с рецептором ampa |
CN105085383B (zh) * | 2015-08-19 | 2017-09-01 | 四川大学 | 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途 |
EP3378863A4 (en) * | 2015-11-13 | 2019-03-06 | Eisai R&D Management Co., Ltd. | PYRANODIPYRIDINVERBINDUNG |
KR101652750B1 (ko) * | 2015-12-03 | 2016-08-31 | 김종선 | 피리딘 및 그 유도체의 정제방법 |
CN117777121A (zh) | 2016-10-24 | 2024-03-29 | 詹森药业有限公司 | 化合物及其用途 |
BR112019009804A2 (pt) | 2016-11-18 | 2019-08-13 | Dow Agrosciences Llc | 4-((6-bromopiridin-3-il)óxi)benzonitri¬la e processos de preparação |
US11826492B2 (en) * | 2016-12-22 | 2023-11-28 | Biotronik Ag | Intratumoral drug delivery materials and methods for treating breast cancer |
JP6241974B1 (ja) | 2017-01-11 | 2017-12-06 | 公立大学法人横浜市立大学 | 霊長類生体の脳内ampa受容体のイメージング方法、プログラム、及びスクリーニング方法 |
GB201702221D0 (en) | 2017-02-10 | 2017-03-29 | Univ Of Sussex | Compounds |
CA3108048A1 (en) * | 2017-07-31 | 2019-02-07 | Washington University | Pirfenidone derivatives for modulation of b lymphocyte activity and organ protection |
EP3700934A4 (en) | 2017-10-24 | 2021-10-27 | Yumanity Therapeutics, Inc. | COMPOUNDS AND USES OF THESE COMPOUNDS |
CN110028442B (zh) * | 2018-01-11 | 2020-07-17 | 新发药业有限公司 | 一种吡仑帕奈的简便制备方法 |
GB201803340D0 (en) * | 2018-03-01 | 2018-04-18 | Univ Of Sussex | Compounds |
EP3560934A1 (en) | 2018-04-26 | 2019-10-30 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Process for the preparation of pure 2-cyanophenylboronic acid and esters thereof, intermediates of perampanel or of e2040 |
BR112021010953A2 (pt) | 2018-12-14 | 2021-08-24 | Eisai R&D Management Co., Ltd. | Formulações farmacêuticas de base aquosa de compostos de 1,2-di-hidropiridina |
CN110483563B (zh) * | 2019-09-06 | 2021-12-28 | 山西医科大学 | 一种新型离子型β-萘酚醛席夫碱锆配合物的制备方法及应用 |
KR102392825B1 (ko) | 2020-02-18 | 2022-04-29 | 명인제약주식회사 | 2-(2-옥소-1-페닐-5-피리딘-2-일피리딘-3-일)벤조니트릴과 l-말릭산의 공결정 화합물 및 이의 제조 방법 |
CN111362930B (zh) * | 2020-04-15 | 2023-02-03 | 安徽医科大学 | 一种1,2,4-噁二唑-吡啶类化合物及其应用 |
WO2023042887A1 (ja) | 2021-09-15 | 2023-03-23 | 国立大学法人 琉球大学 | 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物 |
JPWO2023042888A1 (pt) | 2021-09-15 | 2023-03-23 | ||
CN114057630B (zh) * | 2021-12-23 | 2023-06-02 | 郑州大学 | 吡非尼酮衍生物及其合成方法和应用 |
WO2023230205A1 (en) | 2022-05-25 | 2023-11-30 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
WO2024010585A1 (en) * | 2022-07-07 | 2024-01-11 | Yale University | Non-covalent inhibitors of the main protease of sars-cov-2 and methods of use |
KR20240008565A (ko) * | 2022-07-12 | 2024-01-19 | 이화여자대학교 산학협력단 | 연속 흐름 공정을 포함하는 페람파넬 유도체의 제조 방법 |
US11958832B1 (en) | 2023-10-12 | 2024-04-16 | King Faisal University | 2-alkoxy[4,3:6,3-terpyridine]-3-carbonitriles as antimicrobial compounds |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5283761A (en) * | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Novel pyridone derivative |
JPS5531072A (en) * | 1979-07-30 | 1980-03-05 | Rikagaku Kenkyusho | Preparation of 2-pyridone compound |
DE4003541C1 (pt) * | 1990-02-06 | 1991-08-08 | Alter S.A., Madrid, Es | |
US5356902A (en) | 1992-11-06 | 1994-10-18 | Eli Lilly And Company | Decahydroisoquinoline compounds as excitatory amino acid receptor antagonists |
IL109397A0 (en) | 1993-04-28 | 1994-07-31 | Schering Ag | Quinoxalinedione derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
HU219777B (hu) | 1993-07-02 | 2001-07-30 | Gyógyszerkutató Intézet Kft. | Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására |
RU2149873C1 (ru) | 1994-09-27 | 2000-05-27 | Яманоути Фармасьютикал Ко., Лтд. | 1,2,3,4-тетрагидрохиноксалиндионовые производные и фармацевтическая композиция |
KR100400639B1 (ko) * | 1995-04-27 | 2003-12-31 | 미쯔비시 웰 파마 가부시키가이샤 | 복소환식아미드화합물및그의의약용도 |
AU1050597A (en) | 1995-11-15 | 1997-06-05 | California Institute Of Technology | Synthesis of zeolites by hydrothermal reaction of zeolite p1 |
DE19604920A1 (de) | 1996-02-01 | 1997-08-07 | Schering Ag | Neue 2,3-Benzodiazepinderivate, deren Herstellung und Verwendung als Arzneimittel |
US5891871A (en) | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
HU9600871D0 (en) | 1996-04-04 | 1996-05-28 | Gyogyszerkutato Intezet | New 2,3-benzodiazepine derivatives |
SK284108B6 (sk) | 1996-05-15 | 2004-09-08 | Pfizer Inc. | 2,3-Disubstituované 4(3H)-chinazolinóny, ich použitie a farmaceutické kompozície s ich obsahom |
DE19643037A1 (de) | 1996-10-18 | 1998-04-23 | Boehringer Ingelheim Kg | Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel |
WO1998024780A2 (en) | 1996-12-05 | 1998-06-11 | Amgen Inc. | Substituted pyrimidinone and pyridinone compounds and their use |
EP0968194B1 (en) | 1997-02-28 | 2004-05-26 | Pfizer Products Inc. | Atropisomers of 3-aryl-4(3h)-quinazolinones and their use as ampa-receptor antagonists |
GB9708945D0 (en) | 1997-05-01 | 1997-06-25 | Merck Sharp & Dohme | Therapeutic agents |
GB9711753D0 (en) | 1997-06-06 | 1997-08-06 | Merck Sharp & Dohme | Therapeutic agents |
WO1999031062A1 (fr) * | 1997-12-17 | 1999-06-24 | Shionogi & Co., Ltd. | Nouveaux composes de pyridine |
WO2000001376A2 (en) | 1998-07-02 | 2000-01-13 | Eisai Co., Ltd | Pharmaceutical compositions and their uses for treatment of demyelinating disorders |
DE19835918A1 (de) | 1998-08-07 | 2000-02-10 | Dresden Arzneimittel | Neue antikonvulsiv wirkende 4-Amino-1-aryl-pyridin-2-one und Verfahren zu deren Herstellung |
IL152848A0 (en) | 2000-06-12 | 2003-06-24 | Eisai Co Ltd | 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof |
GB0129260D0 (en) | 2001-12-06 | 2002-01-23 | Eisai London Res Lab Ltd | Pharmaceutical compositions and their uses |
-
2001
- 2001-06-08 IL IL15284801A patent/IL152848A0/xx active IP Right Grant
- 2001-06-08 CN CNB018110525A patent/CN1245386C/zh not_active Expired - Lifetime
- 2001-06-08 AU AU2001262723A patent/AU2001262723C1/en active Active
- 2001-06-08 HU HU0303398A patent/HU229553B1/hu active Protection Beyond IP Right Term
- 2001-06-08 KR KR1020077020875A patent/KR100904011B1/ko active IP Right Grant
- 2001-06-08 AU AU6272301A patent/AU6272301A/xx active Pending
- 2001-06-08 AT AT01936920T patent/ATE420862T1/de active
- 2001-06-08 WO PCT/JP2001/004857 patent/WO2001096308A1/ja active Application Filing
- 2001-06-08 KR KR1020027016890A patent/KR100850728B1/ko active Protection Beyond IP Right Term
- 2001-06-08 DK DK01936920T patent/DK1300396T3/da active
- 2001-06-08 HU HUP1300187 patent/HU1300187D0/hu unknown
- 2001-06-08 EP EP01936920A patent/EP1300396B1/en not_active Expired - Lifetime
- 2001-06-08 CA CA2412172A patent/CA2412172C/en not_active Expired - Lifetime
- 2001-06-08 NZ NZ522773A patent/NZ522773A/en not_active IP Right Cessation
- 2001-06-08 MX MXPA02012314A patent/MXPA02012314A/es active IP Right Grant
- 2001-06-08 KR KR1020077020877A patent/KR100869271B1/ko active IP Right Grant
- 2001-06-08 EP EP09015363A patent/EP2177520A1/en not_active Withdrawn
- 2001-06-08 EP EP09000287A patent/EP2053041A3/en not_active Withdrawn
- 2001-06-08 DE DE60137426T patent/DE60137426D1/de not_active Expired - Lifetime
- 2001-06-08 BR BRPI0111596A patent/BRPI0111596B8/pt not_active IP Right Cessation
- 2001-06-08 PT PT01936920T patent/PT1300396E/pt unknown
- 2001-06-08 US US10/296,719 patent/US6949571B2/en active Active
- 2001-06-08 ES ES01936920T patent/ES2320973T3/es not_active Expired - Lifetime
- 2001-06-08 JP JP2002510451A patent/JP3922368B2/ja not_active Expired - Lifetime
- 2001-06-12 TW TW096134645A patent/TW200815402A/zh not_active IP Right Cessation
- 2001-06-12 TW TW090114146A patent/TWI292757B/zh active
-
2002
- 2002-11-14 IL IL152848A patent/IL152848A/en active Protection Beyond IP Right Term
- 2002-11-14 ZA ZA2002/09270A patent/ZA200209270B/en unknown
- 2002-12-11 NO NO20025955A patent/NO325160B1/no not_active IP Right Cessation
-
2003
- 2003-09-29 HK HK03107029.7A patent/HK1056871A1/xx not_active IP Right Cessation
-
2005
- 2005-07-06 US US11/174,514 patent/US7563811B2/en not_active Expired - Lifetime
-
2006
- 2006-12-13 JP JP2006335187A patent/JP5068069B2/ja not_active Expired - Fee Related
-
2007
- 2007-07-18 IL IL184686A patent/IL184686A/en active IP Right Grant
- 2007-07-18 IL IL184687A patent/IL184687A/en active IP Right Grant
-
2008
- 2008-07-03 IL IL192605A patent/IL192605A/en active IP Right Grant
-
2009
- 2009-02-27 US US12/395,378 patent/US7939549B2/en not_active Expired - Lifetime
- 2009-04-10 CY CY20091100419T patent/CY1108969T1/el unknown
-
2012
- 2012-05-21 JP JP2012115592A patent/JP2012207021A/ja not_active Withdrawn
- 2012-12-10 FR FR12C0074C patent/FR12C0074I2/fr active Active
- 2012-12-12 LU LU92113C patent/LU92113I2/fr unknown
- 2012-12-18 NO NO2012021C patent/NO2012021I2/no unknown
- 2012-12-18 CY CY2012032C patent/CY2012032I2/el unknown
- 2012-12-21 NL NL300565C patent/NL300565I1/nl unknown
-
2013
- 2013-01-03 BE BE2013C003C patent/BE2013C003I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0111596A (pt) | Composto e seu uso, processo para sua produção, composição farmacêutica e processo e método para prevenir ou tratar doenças | |
EA200101133A1 (ru) | Способ ингибирования агрегации амилоидных белков и визуализации амилоидных отложений с использованием производных изоиндолина | |
BR0008056A (pt) | Pirrolocarbazóis e isoindolonas cìclicas fundidas substituìdas | |
NZ516599A (en) | 2-arylimino-2,3-dihydrothiazoles, and their use thereof as somatostatin receptor ligands | |
IL165262A (en) | Kinase inhibitors and pharmaceutical compositions containing them | |
ATE377004T1 (de) | Proteinkinaseinhibitoren | |
EA200500342A1 (ru) | Гетероциклические замещённые пиперазины для лечения шизофрении | |
DE60009511D1 (de) | Nematizide trifluorbutene | |
BRPI0410630A (pt) | antagonista de nk1 | |
BR9910119A (pt) | Derivados heterocìclicos de glicil beta-alanina como antagonistas de vitronectina | |
BR0309486A (pt) | Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas | |
DE69838662D1 (de) | Morphinanderivate und ihre medizinische Anwendung | |
BR0013311A (pt) | Derivados substituìdos de 1,5-dihidropirrol-2-ona eficazes como antagonistas de receptores nmda para o tratamento de estados de dor | |
BRPI0407841A (pt) | inibidores heterocìclicos de quinase | |
EA200301203A1 (ru) | Новые соединения и композиции как ингибиторы катепсина | |
YU44301A (sh) | 5ht1 antagonisti za antidepresantnu terapiju | |
ATE304522T1 (de) | Verfahren zur hemmung von amyloidprotein aggregation und zur diagnostischen nachweis von amyloidablagerung unter verwendung von aminoindanderivaten | |
PL350568A1 (en) | N-(2-phenyl-4-aminobutyl)-1-naphtamides as antagonists of neurokinin 1 receptors | |
DE60134735D1 (de) | Neue neurokinin-antagonisten zum gebrauch als arzneimittel | |
DE60110233D1 (de) | Neue n-(2-phenyl-3-aminopropyl)naphtamide | |
ATE308513T1 (de) | Naphthamid-neurokinin antagonisten zur verwendung als medikamente | |
EA200400409A1 (ru) | Новые соединения изохинолина, способ их получения и фармацевтические композиции, содержащие их | |
EA200100918A1 (ru) | Агонисты 5-ht1f рецептора | |
DE60137451D1 (de) | N-substituierte Amide als NK1 Rezeptor Antagonisten | |
BR0317363A (pt) | Antagonista de npy-5 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: EISAI R AND D MANAGEMENT CO., LTD. (JP) Free format text: TRANSFERIDO DE: EISAI CO., LTD. |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA:INT.CL. C07D213/64, 213/69, 213/81, 213/84, 213/89, 401/04, 401/14, 405/04, 405/14, 409/04, 4"09/14, 413/04, 413/14, 417/04, 417/14, 471/04, 471/06 "9, 31/444, 31/4545, 31/4709, 31/4725 6, 25/18, 25/28, 25/30, 43/00, 9/10 Ipc: C07D 213/64 (2011.01), C07D 213/69 (2011.01), C07D Free format text: PARA:INT.CL. C07D213/64, 213/69, 213/81, 213/84, 213/89, 401/04, 401/14, 405/04, 405/14, 409/04, 409/14, 413/04, 413/14, 417/04, 417/14, 471/04, 471/06; A61K31/4422, 31/443, 31/4433, 31/4436, 31/4439, 31/444, 31/4545, 31/4709, 31/4725; A61P1/00, 1/08, 13/02, 25/00, 25/02, 25/04, 25/08, 25/14, 25/16, 25/18, 25/28, 25/30, 43/00, 9/10 Ipc: C07D 213/64 (2011.01), C07D 213/69 (2011.01), C07D |
|
B09B | Patent application refused [chapter 9.2 patent gazette] |
Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) DA LPI |
|
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/10/2018, OBSERVADAS AS CONDICOES LEGAIS. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 21A ANUIDADE. |
|
B21H | Decision of lapse of a patent or of a certificate of addition of invention cancelled [chapter 21.8 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 21.6 NA RPI NO 2673 DE 29/03/2022 POR TER SIDO INDEVIDA. |
|
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REF. RPI 2491 DE 02/10/2018 QUANTO AO PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/06/2001 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF ) |
|
B21A | Patent or certificate of addition expired [chapter 21.1 patent gazette] |
Free format text: PATENTE EXTINTA EM 08/06/2021 |